MedTrace Logo

Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

NCT04569903 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2025-09-18

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the diagnostic performance of an algorithm in identifying patients with ATTR amyloidosis.

Conditions

  • Transthyretin Amyloidosis

Interventions

DEVICE

Computer algorithm for ATTR

Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm

Sponsors & Collaborators

  • Alnylam Pharmaceuticals Inc

    collaborator UNKNOWN

  • Yale University

    lead OTHER

Principal Investigators

  • Edward Miller, MD · Yale University

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2025-02-01
Completion
2025-02-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04569903 on ClinicalTrials.gov